HIM
PLX icon

Harbour Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

Harbour Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5K Hold
10,100
– – 0.01% 107
2026
Q1 		$21.9K Hold
10,100
– – 0.01% 101
2025
Q4 		$18.2K Hold
10,100
– – 0.01% 99
2025
Q3 		$22.4K Hold
10,100
– – 0.01% 105
2025
Q2 		$14.9K Hold
10,100
– – 0.01% 94
2025
Q1 		$25.9K Hold
10,100
– – 0.01% 96
2024
Q4 		$19K Hold
10,100
– – 0.01% 98
2024
Q3 		$10.3K Hold
10,100
– – ﹤0.01% 91
2024
Q2 		$11.8K Hold
10,100
– – 0.01% 87
2024
Q1 		$12.7K Hold
10,100
– – 0.01% 88
2023
Q4 		$18K Hold
10,100
– – 0.01% 75
2023
Q3 		$16.8K Hold
10,100
– – 0.01% 74
2023
Q2 		$20.2K Buy
+10,100
New +$24.1K 0.01% 74

Other funds holding PLX

SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Harbour Investment Management's PLX Position: Q2 2026 in Review

Harbour Investment Management held its Protalix BioTherapeutics (PLX) position steady in Q2 2026 at 10,100 shares worth $23.5K. The position accounts for 0.01% of the portfolio, ranked #107.

Harbour Investment Management first reported a position in PLX in Q2 2023 and has held it in 13 quarters since. The position peaked at $25.9K in Q1 2025. 9 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Harbour Investment Management held 10,100 shares of Protalix BioTherapeutics worth $23.5K as of Q2 2026.
  • Harbour Investment Management left its Protalix BioTherapeutics share count unchanged in Q2 2026.
  • Protalix BioTherapeutics made up 0.01% of Harbour Investment Management's portfolio in Q2 2026, its #107 holding.
  • Harbour Investment Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 13 quarters since.
  • Harbour Investment Management's Protalix BioTherapeutics position peaked at $25.9K in Q1 2025.
  • 9 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Harbour Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.